In this context, VLCKD may represent a preventive measure in postmenopausal women with obesity, to reduce visceral adipose tissue, inflammatory status, growth factors such as insulin and IGF-1, and to reduce the risk of endometrial cancer. Here, IGF1 is linked to obesity due to melanocortin 4 receptor deficiency.